Is the newest angiotensin‐receptor blocker azilsartan medoxomil more efficacious in lowering blood pressure than the older ones? A systematic review and network meta‐analysis [PDF]
The Journal of Clinical Hypertension, 2021 Angiotensin‐receptor blockers are often considered insufficiently efficacious in reducing blood pressure. However, newer angiotensin‐receptor blockers may be more effective than the older ones.
Ji‐Guang Wang +6 more
doaj +3 more sources
Central Composite Design Implemented Azilsartan Medoxomil Loaded Nanoemulsion to Improve Its Aqueous Solubility and Intestinal Permeability: In Vitro and Ex Vivo Evaluation [PDF]
Pharmaceuticals, 2022 The present research attempted to design and develop a nanoemulsion formulation of azilsartan medoxomil to improve its aqueous solubility and intestinal permeability. Based on the solubility profile, ethyl oleate, tween 80, and Transcutol P were selected
Kamla Pathak +2 more
exaly +4 more sources
A Prospective Study of Azilsartan Medoxomil in the Treatment of Patients with Essential Hypertension and Type 2 Diabetes in Asia [PDF]
International Journal of Hypertension, 2022 This phase 4 study evaluated the efficacy and safety of azilsartan medoxomil (AZL-M) in patients with essential hypertension and type 2 diabetes mellitus (T2DM) in Hong Kong, Taiwan, and Thailand.
Chaicharn Deerochanawong +4 more
doaj +3 more sources
Efficacy and safety of azilsartan medoxomil in the treatment of hypertension: a systematic review and meta-analysis [PDF]
Frontiers in Cardiovascular MedicineBackgroundAngiotensin II receptor blockers (ARBs) are utilized for the management of hypertension and diabetes. Previous meta-analyses suggested that azilsartan medoxomil (AZL-M) improved blood pressure (BP) reduction, but there were no safety findings ...
Xiu-Xia Li
exaly +4 more sources
A randomized trial of the efficacy and safety of azilsartan medoxomil combined with chlorthalidone [PDF]
JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2018 Introduction: We measured the effects of azilsartan medoxomil co-administered with chlorthalidone 25 mg in stage 2 hypertension. Methods: Azilsartan medoxomil 40 or 80 mg plus chlorthalidone were compared with placebo plus ...
Michael Weber
exaly +6 more sources
Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study [PDF]
Epidemiology and HealthOBJECTIVES This study investigated the safety of azilsartan and amlodipine combination therapy versus other angiotensin receptor blockers (ARBs) and amlodipine in patients with hypertension.
Hyesung Lee +9 more
doaj +2 more sources
Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes. [PDF]
Transl Res, 2014 We have shown that glycemic control prevents diabetes‐mediated remodeling of the cerebrovasculature. However, whether the remodeling can be reversed is unknown. Given that angiotensin II Type 1 receptor blockers (ARBs) reverse pathological vascular remodeling and function independent of changes in blood ...
Abdelsaid M, Coucha M, Ergul A.
europepmc +4 more sources
Efficacy and safety of azilsartan medoxomil and telmisartan in hypertensive patients: A randomized, assessor-blinded study [PDF]
Saudi Journal of Medicine and Medical Sciences, 2020 Background: Few studies have compared the safety and efficacy of azilsartan medoxomil (AZL-M) and telmisartan in hypertensive patients, especially using ambulatory blood pressure monitoring (ABPM).
Megha Garg +5 more
doaj +2 more sources
Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial. [PDF]
J Clin Hypertens (Greenwich), 2018 Patients with grade 2‐3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160‐190 mm Hg and 24‐hour SBP 140‐175 mm Hg by ambulatory blood pressure monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL‐M) monotherapy for 4 weeks.
Collier DJ +7 more
europepmc +5 more sources
Efficacy and safety of azilsartan medoxomil, an angiotensin receptor blocker, in Korean patients with essential hypertension [PDF]
Clinical Hypertension, 2018 Background This was a phase 3, randomized, double-blind, placebo-controlled study. Methods Adult Korean patients with essential hypertension and a baseline mean sitting clinic systolic blood pressure (scSBP) ≥150 and ≤180 mmHg were randomized to 6-week ...
Attila Juhasz +4 more
doaj +2 more sources